Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant carcinoid in two brothers.

S Kinova1, I Duris, E Kovacova

  • 1Ist Department of Internal Medicine, University Hospital, Comenius University, Bratislava, Slovakia. kinova@faneba.sk

Bratislavske Lekarske Listy
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Central systolic blood pressure (cSBP) to brachial systolic blood pressure (brachSBP) ratio reproducibility during antihypertensive therapy.

Bratislavske lekarske listy·2021
Same author

The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non-muscle invasive bladder cancer.

Bratislavske lekarske listy·2020
Same author

Testosterone replacement therapy (TRT) and its effect on bone marrow. How serious is it and is there a true polyglobulia?

Bratislavske lekarske listy·2017
Same author

Bone metastases in neuroendocrine tumors.

Bratislavske lekarske listy·2017
Same author

Metabolic syndrome and its effect on aortic stiffness in premenopausal women.

Bratislavske lekarske listy·2013
Same author

[Arterial hypertension in gravidity - a risk factor for cardiovascular diseases].

Vnitrni lekarstvi·2013

Familial malignant carcinoid tumors are rare. This case study details two brothers with malignant neuroendocrine tumors, highlighting differing disease progression and outcomes despite similar treatments.

Area of Science:

  • Oncology
  • Gastroenterology
  • Genetics

Background:

  • Malignant carcinoid tumors, a type of neuroendocrine tumor, have a rare familial occurrence, accounting for approximately 3% of cases.
  • Understanding the genetic and environmental factors contributing to familial carcinoid development is crucial for early diagnosis and effective management.

Observation:

  • The study presents a rare instance of malignant carcinoid occurrence in two brothers, detailing their distinct clinical trajectories.
  • The older brother was diagnosed in 1991 with multiple intestinal carcinoid tumors and liver metastases (histological type III), managed with somatostatin analogue (lanreotide) and interferon alfa, achieving disease stability.
  • The younger brother, diagnosed in 1999, experienced rapid disease progression of a malignant neuroendocrine tumor of the pancreas, characterized as a mixed low-differentiated carcinoid with calcitonin overproduction, and unfortunately succumbed to the illness within ten months despite therapy.

Related Experiment Videos

Findings:

  • The case illustrates significant variability in disease progression and treatment response even within the same family for malignant neuroendocrine tumors.
  • The older brother's condition remained stable with treatment, while the younger brother's disease showed aggressive progression, leading to a fatal outcome.
  • The younger brother's diagnosis of a mixed low-differentiated pancreatic neuroendocrine tumor with calcitonin overproduction underscores the diverse pathological presentations within this rare familial context.

Implications:

  • This case highlights the importance of considering familial predispositions in the diagnosis and management of neuroendocrine tumors.
  • Further research into the genetic underpinnings of familial carcinoid tumors may reveal novel therapeutic targets and improve patient stratification.
  • The contrasting outcomes emphasize the need for personalized treatment strategies tailored to the specific tumor biology and patient characteristics in familial neuroendocrine tumor cases.